Post‐marketing analysis for biosimilar CT‐P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan

BACKGROUND AND AIM: CT‐P13, an infliximab (IFX) biosimilar, was approved for treatment of inflammatory bowel disease. However, no comparison with the originator IFX in this indication has been conducted in Japan where endemic levels of tuberculosis and hepatitis virus infection are not low. We evalu...

Descripción completa

Detalles Bibliográficos
Autores principales: Sagami, Shintaro, Nishikawa, Kiyohiro, Yamada, Fumika, Suzuki, Yasuo, Watanabe, Mamoru, Hibi, Toshifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Gastroenterology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451807/
https://www.ncbi.nlm.nih.gov/pubmed/33450057
http://dx.doi.org/10.1111/jgh.15399

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451807/
https://www.ncbi.nlm.nih.gov/pubmed/33450057
http://dx.doi.org/10.1111/jgh.15399

Ejemplares similares